Moderna said he expects security data in the second half of this month (Representation)
Moderna Inc said on Wednesday that it was on track to report the first data from an advanced stage trial of its investigational coronavirus vaccine later this month, and may file an application for authorization to use it. emergency in the United States in early December.
The company may have to wait two months of monitoring safety data to apply for emergency use authorization in the United States, even after reporting positive interim data on the vaccine’s efficacy.
Moderna said it expects security data in the second half of this month.
The world‘s hopes of getting an effective vaccine soon for the virus that has killed more than a million people were raised on Monday after Pfizer Inc said its COVID-19 vaccine was over 90% effective on the basis the results of the interim tests.
There are no vaccines that have achieved global approval yet, although a few, including Moderna’s, are in their advanced stages.
It was too early to guess the effectiveness of Moderna’s vaccine, CEO Stephane Bancel told a conference at Credit Suisse.
The world should wait for more data to understand whether the use of a particular vaccine would be more widespread, Bancel said.
Moderna, which uses technology similar to Pfizer’s, finished recruiting 30,000 volunteers in its advanced-stage study last month.
Public health experts have said it is likely that more than one vaccine would be needed to control the pandemic.
(This story was not edited by GalacticGaming staff and is auto-generated from a syndicated feed.)
